Clinical trials: Sirolimus, completed
Coronary Artery Disease
DES Versus BiOSS LIM - POLBOS II Study
Coronary bifurcation lesions pose therapeutic problems during percutaneous coronary interventions (PCI) and are associated with higher rates of periprocedural complications as well as higher rates of in-stent restenosis and stent…
- Trial name
- POLBOS II (NCT02198300)
- Testing
- Coronary angioplasty with stent implantation, Dual antipletlet therapy (DAPT)
- Where
- Poland
- Volunteers
- 202 people
- Sponsor
- Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
Heart Failure
Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults
The purpose of this research is to see if the drug rapamycin will improve the heart's ability to pump by improving your oxygen consumption.
- Trial name
- NCT04996719
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Marginal Zone B-cell Lymphoma
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
This is a multicenter open-label uncontrolled phase II study. There are no previous clinical data to estimate the expected response rate of everolimus in MALT lymphomas and in the other less common MZLs (i.e.
- Trial name
- NCT01164267
- Testing
- Everolimus
- Where
- 10 sites in Austria, Italy and 1 more
- Volunteers
- 30 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Lymphangioleiomyomatosis (LAM)
Glutamine PET Imaging in LAM
In this study, subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such as sirolimus or everolimus to undergo a PET/CT scan…
- Trial name
- NCT04388371
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Vanderbilt University Medical Center
Advanced Cancers
Lapatinib With Sirolimus or Metformin
The goal of this clinical research study is to find the highest tolerable dose of 2 different combinations of drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01087983
- Testing
- Lapatinib, Sirolimus, Metformin
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Transplantation
To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.
Primary objective of this study is to compare the two therapy regimens with regard to renal function by using calculated creatinine clearance.
- Trial name
- RESTORE (NCT00296361)
- Testing
- Tacrolimus
- Where
- 59 sites in Australia, Austria and 12 more
- Volunteers
- 634 people
- Sponsor
- Astellas Pharma Inc
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
RAD001 in Advanced Hepatocellular Carcinoma
Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped.
- Trial name
- NCT00516165
- Testing
- RAD001
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Uveitis, Intermediate Uveitis
Sirolimus as Therapeutic Approach to Uveitis
The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential…
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- SAVE (NCT00908466)
- Testing
- Sirolimus (rapamycin)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Renal Cell Carcinoma
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa.
- Trial name
- INTORACT (NCT00631371)
- Testing
- Bevacizumab, Temsirolimus, Interferon-Alfa 9MU
- Where
- 172 sites in United States, Argentina and 28 more
- Volunteers
- 791 people
- Sponsor
- Pfizer
Multiple Sclerosis, Relapsing-Remitting
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
- Trial name
- NCT00228397
- Testing
- CCI-779
- Volunteers
- 221 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Sarcopenia
Nutritional and Contractile Regulation of Muscle Growth
Muscle wasting, which involves the loss of muscle tissue, is common in many conditions, such as cancer, AIDS, trauma, kidney failure, bone fracture, and sepsis.
- Trial name
- NCT00891696
- Testing
- Rapamycin, Amino acid supplementation, Low-intensity resistance exercise
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Acute Coronary Syndrome, Angina Pectoris
Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- BIO-RESORT (NCT01674803)
- Testing
- Orsiro, Synergy, Resolute Integrity
- Where
- Netherlands
- Volunteers
- 3,514 people
- Sponsor
- Foundation of Cardiovascular Research and Education Enschede
Transplantation Infection, Cytomegalovirus Infections
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
This is a 12-month single center, randomized, open-label, single center study designed to compare the safety and efficacy of everolimus and very low dose tacrolimus versus enteric-coated sodium mycophenolate and low tacrolimus…
- Trial name
- NCT02084446
- Testing
- Everolimus, Very Low Tacrolimus, Low Tacrolimus
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Ronaldo de Matos Esmeraldo, MD
Coronary Heart Disease
The First-In-Man Pilot Study of Firehawk
This is a small-scale pilot clinical study of the Rapamycin-Eluting Coronary Stent System of Microport for the first time to assess the preliminary safety and feasibility used in the human body.
- Trial name
- NCT02688829
- Testing
- Rapamycin target-eluting Coronary Stent System
- Volunteers
- 21 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Malignant Advanced Solid Tumors, Carcinoma, Renal Cell
Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
The aim of the study is to determine the MTD of the combination of everolimus plus axitinib in solid tumors, especially RCC.
- Trial name
- EVAX (NCT01334073)
- Testing
- Axitinib plus everolimus
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Bordeaux
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02890069
- Testing
- PDR001, LCL161, Everolimus
- Where
- 25 sites in United States, Germany and 5 more
- Volunteers
- 298 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Peripheral Arterial Disease
The Cre8™ BTK Post Market Clinical Follow-up Study
Cre8™ BTK is a CE marked drug eluting stent, integrally coated with i-Carbofilm, loaded with formulated Sirolimus for the treatment of infrapopliteal peripheral artery disease.
- Trial name
- NCT05616156
- Testing
- Cre8™ BTK
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- CID S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.